Latest Ratios: P/E Ratio 17.8x · EV/EBITDA 11.3x · ROE 1.1%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $420M | $441M | $510M | $671M | $846M | $1.1B | $1.0B | $801M | $509M | $416M | $261M |
| Enterprise Value | $953M | $974M | $995M | $1.1B | $1.2B | $1.4B | $1.2B | $993M | $655M | $508M | $310M |
| P/E Ratio → | 17.77 | 212.14 | — | 133.20 | 44.20 | 54.33 | 58.89 | 115.84 | 115.32 | 147.89 | 95.96 |
| P/S Ratio | 3.34 | 3.64 | 4.40 | 5.95 | 8.66 | 12.14 | 13.43 | 13.16 | 10.47 | 11.15 | 10.35 |
| P/B Ratio | 0.92 | 1.03 | 1.07 | 1.31 | 1.70 | 2.38 | 2.36 | 2.27 | 1.22 | 1.11 | 1.07 |
| P/FCF | 5.63 | 12.28 | 14.89 | 15.83 | 16.95 | 22.38 | 24.57 | 28.61 | 25.62 | 19.83 | 19.53 |
| P/OCF | 7.45 | 7.81 | 8.66 | 10.94 | 14.03 | 19.52 | 21.01 | 24.75 | 20.84 | 18.81 | 17.46 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 8.04 | 8.60 | 9.57 | 12.20 | 15.09 | 16.21 | 16.33 | 13.47 | 13.59 | 12.31 |
| EV / EBITDA | 11.32 | 15.26 | 15.82 | 16.48 | 17.77 | 21.31 | 22.96 | 23.98 | 19.49 | 19.87 | 17.98 |
| EV / EBIT | 47.03 | 24.86 | 48.49 | 41.85 | 35.12 | 41.16 | 43.95 | 52.00 | 71.56 | 68.71 | 80.16 |
| EV / FCF | — | 27.12 | 29.07 | 25.47 | 23.88 | 27.82 | 29.66 | 35.49 | 32.95 | 24.17 | 23.23 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 8.7% | 8.7% | 80.3% | 81.6% | 83.0% | 83.3% | 82.0% | 79.9% | 79.6% | 76.8% | 81.2% |
| Operating Margin | 16.7% | 16.7% | 17.4% | 22.2% | 34.7% | 36.3% | 36.9% | 30.7% | 27.6% | 19.8% | 15.4% |
| Net Profit Margin | 4.2% | 4.2% | -2.7% | 6.8% | 22.5% | 24.8% | 25.2% | 13.8% | 9.1% | 9.4% | 10.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 1.1% | 1.1% | -0.6% | 1.5% | 4.6% | 5.0% | 4.9% | 2.2% | 1.1% | 1.1% | 1.5% |
| ROA | 0.5% | 0.5% | -0.3% | 0.8% | 2.7% | 3.2% | 3.1% | 1.7% | 1.1% | 1.1% | 1.4% |
| ROIC | 1.6% | 1.6% | 1.6% | 2.1% | 3.2% | 3.6% | 3.5% | 2.5% | 2.0% | 1.5% | 1.3% |
| ROCE | 2.8% | 2.8% | 2.4% | 2.8% | 4.3% | 4.8% | 4.8% | 4.0% | 3.5% | 2.3% | 2.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.25 | 1.25 | 1.03 | 0.80 | 0.72 | 0.58 | 0.50 | 0.55 | 0.35 | 0.25 | 0.21 |
| Debt / EBITDA | 8.40 | 8.40 | 7.79 | 6.29 | 5.32 | 4.20 | 3.99 | 4.69 | 4.40 | 3.66 | 2.96 |
| Net Debt / Equity | — | 1.24 | 1.02 | 0.80 | 0.70 | 0.58 | 0.49 | 0.55 | 0.35 | 0.24 | 0.20 |
| Net Debt / EBITDA | 8.35 | 8.35 | 7.72 | 6.24 | 5.16 | 4.16 | 3.94 | 4.65 | 4.34 | 3.57 | 2.87 |
| Debt / FCF | — | 14.84 | 14.18 | 9.64 | 6.93 | 5.44 | 5.09 | 6.88 | 7.33 | 4.34 | 3.70 |
| Interest Coverage | 1.15 | 1.15 | 0.87 | 1.45 | 2.86 | 3.15 | 3.24 | 2.05 | 1.45 | 1.87 | 3.28 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.17 | 0.17 | 0.25 | 5.74 | 4.39 | 1.98 | 0.77 | 1.66 | 0.70 | 7.72 | 3.49 |
| Quick Ratio | 0.17 | 0.17 | 0.25 | 5.74 | 4.39 | 1.98 | 0.77 | 1.66 | 0.72 | 7.79 | 3.56 |
| Cash Ratio | 0.01 | 0.01 | 0.02 | 0.29 | 0.74 | 0.10 | 0.06 | 0.08 | 0.04 | 0.53 | 0.44 |
| Asset Turnover | — | 0.12 | 0.12 | 0.12 | 0.11 | 0.12 | 0.11 | 0.11 | 0.11 | 0.10 | 0.10 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 13.6% | 12.2% | 10.1% | 7.2% | 5.3% | 3.9% | 3.7% | 4.0% | 5.8% | 5.9% | 6.8% |
| Payout Ratio | 1051.9% | 1051.9% | — | 623.0% | 202.0% | 188.5% | 199.4% | 381.4% | 667.2% | 696.1% | 653.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.6% | 0.5% | — | 0.8% | 2.3% | 1.8% | 1.7% | 0.9% | 0.9% | 0.7% | 1.0% |
| FCF Yield | 17.8% | 8.1% | 6.7% | 6.3% | 5.9% | 4.5% | 4.1% | 3.5% | 3.9% | 5.0% | 5.1% |
| Buyback Yield | 0.4% | 0.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 14.0% | 12.6% | 10.1% | 7.2% | 5.3% | 3.9% | 3.7% | 4.0% | 5.8% | 5.9% | 6.8% |
| Shares Outstanding | — | $27M | $27M | $25M | $24M | $23M | $22M | $19M | $18M | $15M | $11M |
Includes 30+ ratios · 12 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CHCT stock.
Community Healthcare Trust Incorporated's current P/E ratio is 17.8x. The historical average is 95.7x.
Community Healthcare Trust Incorporated's current EV/EBITDA is 11.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 19.6x.
Community Healthcare Trust Incorporated's return on equity (ROE) is 1.1%. The historical average is 1.8%.
Based on historical data, Community Healthcare Trust Incorporated is trading at a P/E of 17.8x. Compare with industry peers and growth rates for a complete picture.
Community Healthcare Trust Incorporated's current dividend yield is 13.58% with a payout ratio of 1051.9%.
Community Healthcare Trust Incorporated has 8.7% gross margin and 16.7% operating margin. Operating margin between 10-20% is typical for established companies.
Community Healthcare Trust Incorporated's Debt/EBITDA ratio is 8.4x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Dividend coverage and leverage strain
Metrics are mathematically derived from official filings.
Discount to Book Masks Thin Earnings Support
Based on CHCT's reported figures, the stock trades at 15.3x P/FFO and 0.92x book value, a discount to book that may reflect market skepticism about FFO durability given quarterly swings from negative 0.06 to 0.94 per share.
The 13.6% dividend yield appears to price in meaningful risk rather than signal a bargain, since FFO per share has been volatile across the ten reported quarters. P/AFFO cannot be reliably calculated because AFFO has turned negative in some periods, so investors should monitor whether run-rate AFFO stabilizes before treating the P/FFO multiple as a reliable anchor. The GAAP P/E of 190 reflects heavy depreciation rather than operating weakness and should not be used for valuation.
Dividend Coverage Hinges on Volatile AFFO
According to recent SEC filings, CHCT's FFO payout ratio reached 105.0% in 2026Q2 and 103.5% in 2026Q1, while AFFO per share of 0.17 in 2026Q3 covers the dividend only partially, suggesting distributions may exceed recurring cash generation.
Payout ratios above 100% in several recent quarters indicate that distributions have frequently consumed all or more than the cash generated, a pattern that may not be sustainable without external funding. The sharp 2026Q3 AFFO decline relative to FFO points to recurring capital needs absorbing distributable cash. Investors should monitor whether management addresses the payout gap through reduced distributions, asset sales, or improved AFFO before assuming the high yield is durable.
Debt-to-Assets Rising With Thin Coverage
Based on CHCT's reported figures, debt-to-equity rose from 0.93 in 2024Q2 to 1.36 in 2026Q2, while interest coverage fell to 1.28x in 2026Q2 and was negative in 2025Q2 and 2024Q2, leaving limited cushion against refinancing or rate pressure.
The steady climb in leverage alongside shrinking book equity suggests the asset base has grown largely through debt rather than retained earnings. Interest coverage near 1.3x in most recent quarters, with negative readings in two periods, indicates little margin for operating shortfalls. The supplied data does not disclose debt maturity schedule or fixed-rate mix, so refinancing exposure warrants further investigation.
NOI Margins Stable Despite Erratic FFO
As reported in financial statements, CHCT's NOI margin held between 79.7% and 81.4% across most recent quarters, indicating property-level economics are steady even as FFO per share swung from negative 0.06 to 0.51.
The consistency of NOI margins suggests the core healthcare property portfolio generates predictable operating income. FFO volatility appears driven more by non-property items, interest expense, and quarterly discontinuities than by deterioration in property economics. The 10.7% and 42.9% readings in two quarters appear to be outliers that warrant further investigation rather than evidence of a trend.
Leverage and Yield Compare Unfavorably to Peers
Based on peer data, CHCT's debt-to-equity of roughly 1.36 sits between NETSTREIT at 0.77 and NexPoint Residential at 5.18, while its 13.6% dividend yield is at the high end of the peer group alongside GMRE at 11.8%.
CHCT's leverage is higher than NETSTREIT's and far below NexPoint's, placing it in a middle band that offers neither the balance sheet strength of the strongest peers nor the distress signals of the most levered. Its 15.3x P/FFO and 0.92x price-to-book sit comparably with GMRE's discount-to-book valuation, suggesting the market is pricing healthcare REITs of this profile with similar caution. Investors should compare payout coverage against peers before concluding the yield is attractive on a relative basis.
P/E Misleads Given Depreciation Drag
The most commonly misapplied metric here is the trailing P/E of 190, which is distorted by real estate depreciation and obscures the operating earnings that FFO is designed to capture.
Applying a standard P/E to a REIT penalizes it for non-cash depreciation charges that do not reflect economic decline in healthcare properties. The more appropriate substitutes are P/FFO and P/AFFO, with AFFO adjusted for recurring capex to reflect distributable cash. Even these metrics require caution given the volatile quarterly series and negative readings in some periods, so a normalized multi-quarter average should be used rather than any single quarter.